Πλοήγηση ανά Θέμα "non small cell lung cancer"
Αποτελέσματα 1-20 από 22
-
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors
(2017)Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. At the time of diagnosis, a large percentage of NSCLC patients have already developed metastasis, responsible for extremely high mortality rates. ... -
Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naïve advanced or metastatic non-small cell lung cancer (NSCLC)
(2021)We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA ... -
Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer
(2017)Purpose: Τo investigate the potential diagnostic and prognostic role of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) serum levels in non-small cell lung cancer (NSCLC). Methods: One hundred ... -
CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
(2019)Background: Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed death ligand (PD-L)1 axis, this study was designed in order to evaluate whether there is a correlation ... -
Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9
(2016)Osteopontin (OPN) is a multifunctional cytokine involved in carcinogenesis. Serum levels of OPN, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9) were measured by ELISA in 90 lung cancer ... -
DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment
(2021)Osimertinib has been an effective second-line treatment in EGFR mutant NSCLC patients; however, resistance inevitably occurs. DNA methylation has been previously implicated in NSCLC progression and often in therapy resistance, ... -
Epithelial-mesenchymal transition in non small-cell lung cancer
(2017)Background/Aim: Lung cancer is the first cause of cancer related deaths in both males and females. Epithelial-mesenchymal transition (EMT) is a reversible process by which epithelial cells transform to mesenchymal stem ... -
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach
(2019)Oncology is currently a sector of medical science with accelerated progress due to rapid technological development, the advancement in molecular biology, and the invention of many innovative therapies. Immunotherapy partially ... -
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
(2017)Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing ... -
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece
(2020)Background: Abundant evidence supports an association between Idiopathic Pulmonary Fibrosis (IPF) and lung cancer development. Data on diagnosis and management of patients with IPF and lung cancer are still scarce. Patients ... -
Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives
(2022)Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have ... -
Myeloid-derived suppressor cells: Major figures that shape the immunosuppressive and angiogenic network in cancer
(2019)Myeloid-derived suppressor cells (MDSCs) constitute a vast population of immature myeloid cells implicated in various conditions. Most notably, their role in cancer is of great complexity. They exert immunosuppressive ... -
Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: Tumor mutation burden and PD-L1 ≥50%
(2018)[No abstract available] -
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
(2020)Background: During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed ... -
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer
(2019)The integration of immunotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC) has revolutionized the approach of the prevalent type of lung cancer. Although PD-1 and its ligands (PD-L1 and PD-L2) are ... -
Pleural effusion levels of dj-1 are increased in elderly lung cancer patients with malignant pleural effusions
(2015)Objectives: DJ-1 is a multifunctional protein implicated in redox dependent cell fate decisions. The aim of ourstudy was to determine the pleural fluid (PF) levels of DJ-1 in malignant pleural effusions (MPEs) secondary ... -
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
(2022)Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records ... -
Small extracellular vesicles in pre-therapy plasma predict clinical outcome in non-small-cell lung cancer patients
(2021)The potential use of plasma-derived small extracellular vesicles (sEV) as predictors of response to therapy and clinical outcome in chemotherapy-naïve patients with non-small-cell lung cancer (NSCLC) was explored. sEV were ...